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Abstract
The Disease Control Priorities program (DCP) has pioneered the use of economic evidence in health. The 
theory of change (ToC) put forward by Norheim is a further welcome and necessary step towards translating 
DCP evidence into better priority setting in low- and middle-income countries (LMICs). We also agree that 
institutionalising evidence for informed priority-setting processes is crucial. Unfortunately, there have been 
missed opportunities for the DCP program to challenge ill-judged global norms about opportunity costs and too 
little respect has been shown for the wider set of local circumstances that may enable, or disable, the productive 
application of the DCP evidence base. We suggest that the best way forward for the global health community is 
a new platform that integrates the many existing development initiatives and that is driven by countries’ asks.
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Introduction
The Disease Control Priorities program (DCP) generated 
influential volumes of evidence for informing global health 
spending priorities and catalysed an international culture shift 
in the use of economic evidence for health. There is, however, 
still far to go before countries actually have the capacities to 
set their own priorities for achieving and sustaining universal 
health coverage (UHC). 
Since DCP1, the project’s main audience has been global 
funders and advocates. The next challenge is how best to 
engage governments. It has been proven repeatedly that 
making priority setting evidence available is not enough 
alone to bring about policy change.1 Norheim proposes a 
theory of change (ToC) for “better priority-setting.”2 The 
ToC sets out the causal steps and assumptions that would 
enable the achievement of short-term DCP outcomes as well 
as intermediate- and long-term country outcomes. The steps 
include building capacity, institutionalising priority-setting 
and, the ultimate goal: resource allocation informed by 
epidemiological and economic evidence. Such a ToC would 
be a natural next step for DCP, whose sole mission to date 
has been generating global evidence, but evidence that has not 
been tailored to the needs of specific countries.
Norheim underlines the importance of country context. 
He cautions that not all contextual factors can be influenced 
by programs like DCP. However, DCP, together with like 
motivated initiatives such as the International Decision 
Support Initiative (iDSI) and the global health community, 
may be able to deliver the ultimate goal. Together, these 
initiatives can go far to shape contexts and build supportive 
environments for low- and middle-income countries (LMICs) 
aiming at UHC.
Taking Pride in Cost-Effectiveness
DCP1’s greatest achievement was that it got the global 
development community to recognise the importance of 
maximising the impact of healthcare resources through cost-
effectiveness analysis. It catalysed an international culture 
shift towards the use of economic evidence in health resource 
allocation. As Norheim2 points out, this shift has been 
embraced by many countries, the World Health Organization 
(WHO) and major donors, including the Bill and Melinda 
Gates Foundation. The Foundation remains one of the world’s 
biggest largest external funders for global health and exerts 
huge influence both directly and indirectly via conduits such 
as the Global Fund and Gavi.3
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Norheim draws attention to criticisms of earlier versions of 
DCP, notably the use of cost-effectiveness as a key criterion 
for decision-making to the exclusion of affordability, ethics, 
equity, legitimacy and human rights. These criteria are, 
however, far from being inherently incompatible with 
cost-effectiveness – but they need integrating into a more 
comprehensive method of appraisal and implemented 
through institutions that understand the importance of 
each. Cost-effectiveness is already a form of applied ethics (a 
species of utilitarianism) but needs further supplementation4-7 
and appropriately designed institutions and decision-making 
procedures. It is unquestionably true that “health policy 
needs to go beyond cost-effectiveness”2 but this ought not to 
be interpreted in a negative way. Cost-effectiveness needs to 
be supplemented not supplanted: “where economic evidence 
is down-valued or even deprioritised over other socially 
acceptable considerations…risks throwing the baby out 
with the bathwater.”8 The world needs more, not less, cost-
effectiveness analysis8 – so long as it respects each country’s 
values and circumstances.
As Norheim notes, DCP3 centred on advancing UHC with a 
focus on economic feasibility by selecting the “highest priority 
package that could be implemented first and at less cost.” Yet, 
the cost of the highest priority package was typically still larger 
than the average public spend per capita on health in low-
income countries.9 One needs to ask: economic feasibility for 
whom? and “feasibility from what perspective?” These are the 
first questions any useful economic analysis should address. 
The global health community has paid insufficient attention 
to these issues.10 It is as though differences in history, culture, 
social values, priorities for other sectors, political feasibility, 
and available budgets were not significant differentiating 
factors among nations. This may partially explain why the 
real-world uptake of DCP and other economic evidence in 
resource allocation decisions has been disappointing. It often 
simply did not fit.
Opportunity Costs and Missed Opportunities
Despite the WHO’s and the World Bank’s cost-effectiveness 
advocacy, DCP has not used its significant global influence to 
challenge questionable global norms. For instance, Millennium 
Development Goals (MDGs) targets are disconnected 
from national budgets, as are WHO Standard Treatment 
Guidelines11 and Essential Medicines Lists.12 Until recently,13 
WHO CHOICE was associated with the 1-3x gross domestic 
product (GDP) guidance for willingness-to-pay thresholds, 
which generally underestimate actual opportunity costs of 
health interventions in LMICs.14 The ill effects can be lasting. 
WHO has not replaced its threshold recommendations with 
any new practical guidance, so countries struggle to apply 
health technology assessment (HTA) while many researchers 
and public servants mistakenly continue to use 1-3x GDP in 
the absence of anything better. Such guidance can do more 
harm than good for LMICs already struggling to achieve 
UHC within constrained budgets.15
If policy-makers are to look to DCP for guidance, a good 
start for DCP would be to acknowledge the importance of the 
constraints and opportunity costs that underpin thresholds 
and budget impacts. Much greater emphasis also needs to be 
placed on data and the interpretation of data from outside the 
country. There is now substantive work on the transferability 
of evidence between contexts. Strengthening the robustness 
and local applicability of DCP evidence would increase its 
global credibility and simultaneously make DCP knowledge 
more readily interpretable in individual country settings.1,16
 
Putting a Theory of Change Into Practice 
DCP-style evidence has not been generated in response to 
specific local needs. Nonetheless, there have been successful 
attempts to adapt and apply DCP locally to facilitate change. 
In the Philippines, global DCP evidence filled a local gap 
and informed sound policy decisions serving “as a credible, 
temporary solution…while countries continue their efforts 
in developing local capacity to generate data.”17 Lists of 
priority interventions were “a necessary first step to start a 
more formal priority setting process” in the Philippines 
intended eventually to be housed in an independent HTA 
agency,17 which will advise the Ministry of Health on service 
expansions. 
Having country-specific ToCs for translating economic 
evidence into policy decisions and institutionalising this 
process would greatly enhance the usefulness of extended 
cost-effectiveness analysis and would be a step towards the 
local targeting of evidence generation. Norheim’s proposed 
DCP ToC bears similarities to the iDSI ToC (Figure).18 We 
have successfully tried-and-tested the iDSI ToC for building 
countries’ priority-setting capacities and establish institutional 
mechanisms which in turn result in evidence-informed, cost-
effective and equitable decisions.19
Norheim leaves unanswered a big question: whose 
responsibility is it to operationalise DCP’s ToC? Does DCP 
see itself evolving as an evidence generating initiative, a force 
for capacity-building, a technical assistance initiative, or all 
three? Norheim is right that priority-setting is ultimately 
the responsibility of each country (or consortia of like-
minded countries), yet there is a clear unmet need to support 
countries’ capacity-building efforts to conduct and interpret 
research16 and to institutionalise the capacity for such things. 
Help, for the time being, will need to come from outside. DCP 
ought to be a part of that help but it cannot provide it alone.
Going Further as a Global Community
The global health community should move beyond a 
piecemeal, project-by-project approach to research, beyond 
advocacy and exhortation, and beyond knowledge sharing. It 
must not continue powerless to shape the contextual factors 
that Norheim considers critical for sustainable systems of 
effective resource allocations that generate best value for 
money in health.
We need a global community of practice that diffuses global 
knowledge into practice through country-led and country-
owned policy mechanisms. This community could include 
DCP, iDSI, Global Burden of Disease, Tufts’ Cost-Effective 
Analysis registry, HIV/TB/malaria modelling consortia, 
Global Health Costing Consortium, Joint Learning Network, 
and capacity building platforms (eg, Strategic Purchasing 
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African Resource Center), and others.
Such a community would be a truly grand consortium 
for transitioning LMICs20 through coordinated, national-
level reforms delivering comprehensive and affordable UHC 
packages. The aspiration gap is enormous21 but the demand 
is real. DCP, with iDSI and other like-minded initiatives 
and funders, can together articulate that joined-up offer. 
We suggest a new platform, in which multiple initiatives are 
merged and driven by the needs articulated by individual 
countries, is the way to do it.
What sort of platform might this be? We would welcome 
ideas on how this might be achieved with minimal 
interference with the independence of but in such a fashion 
as to help LMICs develop strategies for creating supportive 
political and professional environments for the application 
of cost-effective evidence in decision about public insured 
benefits. This should be supplemented where appropriate 
by evidence on other criteria (such as population coverage, 
equity and financial protection, and including Norheim’s 
criteria), and further supplemented by the establishment of 
agencies or specialised in-country groups to provide and 
evaluate such evidence and by training programs both for 
building capacity in the technical skills needed and for the 
non-technical partners in decision making processes. Not 
least, work on informing the wider public of health service 
users and taxpayers would further complement these efforts.
That these intentions would be better for being coordinated 
in some fashion seems to us to be self-evident. Would it be 
worth the effort – and whose effort it ought to be? On this, we 
would welcome a debate.
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